EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Antonio Omuro, Alba A Brandes, Antoine F Carpentier, Ahmed Idbaih iD, David A Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent iD, Oliver Bähr, Giuseppe Lombardi iD, Paul Mulholland und 17 weitere

Neuro-Oncology · 05.01.2023 · 25 (1) · 123-134

DOI: 10.1093/neuonc/noac099 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, online erschienen am 14.04.2022. Verfasst von Antonio Omuro und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 534-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Bristol Myers Squibb, Princeton, NJ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim of this open-label, phase III CheckMate 498 study was to evaluate the efficacy of nivolumab (NIVO) + RT compared with TMZ + RT in newly diagnosed GBM with unmethylated MGMT promoter.

Methods

Patients were randomized 1:1 to standard RT (60 Gy) + NIVO (240 mg every 2 weeks for eight cycles, then 480 mg every 4 weeks) or RT + TMZ (75 mg/m2 daily during RT and 150–200 mg/m2/day 5/28 days during maintenance). The primary endpoint was OS.

Results

A total of 560 patients were randomized, 280 to each arm. Median OS (mOS) was 13.4 months (95% CI, 12.6 to 14.3) with NIVO + RT and 14.9 months (95% CI, 13.3 to 16.1) with TMZ + RT (hazard ratio [HR], 1.31; 95% CI, 1.09 to 1.58; P = .0037). Median progression-free survival was 6.0 months (95% CI, 5.7 to 6.2) with NIVO + RT and 6.2 months (95% CI, 5.9 to 6.7) with TMZ + RT (HR, 1.38; 95% CI, 1.15 to 1.65). Response rates were 7.8% (9/116) with NIVO + RT and 7.2% (8/111) with TMZ + RT; grade 3/4 treatment-related adverse event (TRAE) rates were 21.9% and 25.1%, and any-grade serious TRAE rates were 17.3% and 7.6%, respectively.

Conclusions

The study did not meet the primary endpoint of improved OS; TMZ + RT demonstrated a longer mOS than NIVO + RT. No new safety signals were detected with NIVO in this study. The difference between the study treatment arms is consistent with the use of TMZ + RT as the standard of care for GBM. ClinicalTrials.gov NCT02617589

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTemozolomideNivolumabDisease-Free SurvivalProgression-Free SurvivalAntineoplastic Agents, AlkylatingDNA Modification MethylasesTumor Suppressor ProteinsDNA Repair Enzymes

Stichwörter der Autor:innen

newly diagnosed glioblastomanivolumabradiotherapytemozolomideunmethylated MGMT

Substanzen

TemozolomideNivolumabAntineoplastic Agents, AlkylatingMGMT protein, humanDNA Modification MethylasesTumor Suppressor ProteinsDNA Repair Enzymes

Autor:innen und Institutionen

  • Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy.
  • Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Service de Neurologie, Paris, France.
  • Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital Universitaire La Pitié Salpêtrière, DMU Neurosciences, Paris, France.
  • Dana-Farber Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Ahmed Idbaih, Martin van den Bent, Giuseppe Lombardi, Ghazaleh Tabatabai, Mustafa Khasraw, Michael Weller

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Bristol Myers Squibb, Princeton, NJ

Zitieren

APA

Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., Lombardi, G., Mulholland, P., Tabatabai, G., Lassen, U., Sepulveda, J. M., Khasraw, M., Vauleon, E., Muragaki, Y., Di Giacomo, A. M., …, & Weller, M. (2023). Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 25(1), 123-134. https://doi.org/10.1093/neuonc/noac099

Vancouver

Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology. 2023;25(1):123-134. doi:10.1093/neuonc/noac099

BibTeX
@article{Omuro2023,
  author = {Omuro, Antonio and Brandes, Alba A and Carpentier, Antoine F and Idbaih, Ahmed and Reardon, David A and Cloughesy, Timothy and Sumrall, Ashley and Baehring, Joachim and van den Bent, Martin and Bähr, Oliver and Lombardi, Giuseppe and Mulholland, Paul and Tabatabai, Ghazaleh and Lassen, Ulrik and Sepulveda, Juan Manuel and Khasraw, Mustafa and Vauleon, Elodie and Muragaki, Yoshihiro and Di Giacomo, Anna Maria and Butowski, Nicholas and Roth, Patrick and Qian, Xiaozhong and Fu, Alex Z and Liu, Yanfang and Potter, Von and Chalamandaris, Alexandros-Georgios and Tatsuoka, Kay and Lim, Michael and Weller, Michael},
  title = {Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {1},
  pages = {123--134},
  doi = {10.1093/neuonc/noac099}
}
Kostenlos starten →